Singapore markets open in 4 hours 35 minutes

DexCom, Inc. (DXCM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
116.53+0.58 (+0.50%)
At close: 04:00PM EDT
116.53 0.00 (0.00%)
After hours: 04:20PM EDT

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200

IndustryMedical Devices
Full-time employees9,500

Key executives

NameTitlePayExercisedYear born
Mr. Kevin Ronald SayerExecutive Chairman, CEO & President3.23MN/A1958
Mr. Jereme M. SylvainExecutive VP, CFO & Chief Accounting Officer1.13MN/A1980
Mr. Jacob Steven LeachExecutive VP & COO1.29MN/A1978
Mr. Michael Jon BrownExecutive VP & Chief Legal Officer1.22MN/A1970
Ms. Teri LawverExecutive VP & Chief Commercial Officer1.41MN/A1967
Mr. Girish NaganathanExecutive VP & CTO423.92kN/A1977
Stacey StewartSenior VP & Chief Information OfficerN/AN/AN/A
Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsN/AN/AN/A
Mr. Matthew DolanExecutive Vice President of Strategy, Corporate Development & Dexcom LabsN/AN/A1981
Ms. Leverne MarshExecutive Vice President of MarketingN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Corporate governance

DexCom, Inc.’s ISS governance QualityScore as of 1 June 2024 is 4. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 6; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.